Trial Profile
A Study to Evaluate the Incidence and Clinical Characteristics of Interstitial Lung Disease (ILD) Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKIs) Gefitinib or Erlotinib in Taiwanese Patients with Adavanced Non Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 19 Dec 2015 New trial record